期刊文献+

吡格列酮对链脲佐菌素诱导的糖尿病大鼠肾脏保护作用研究 被引量:2

原文传递
导出
出处 《中华内科杂志》 CAS CSCD 北大核心 2003年第8期579-580,共2页 Chinese Journal of Internal Medicine
基金 天津市教委科研基金资助项目 (9910 0 6)
  • 相关文献

参考文献1

二级参考文献22

  • 1Corton JC,Anderson SP, Stauber A. Centrol role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Ann Rev Pharmcal Toxicol, 2000, 40:491~518.
  • 2Guan Y, Breyer MD.Peroxisome proliferator-activated receptors(PPARs): novel therapeutic targets in renal disease. Kidney Int, 2001, 60(1): 14~30.
  • 3JUGE-Aubry CE, Hamma E, Siegrist-kaiser C, et al. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor a by phosphorylation of a ligand-independent trans-activating domain. J Biol Chem, 1999,274(15): 10 505~10.
  • 4Kersten S, seydoux J, peters JM, et al. Peroxisome proliferator-activated alpha mediates the adaptive response to fasting. J Clin Invest, 1999, 103(11):1489~98.
  • 5Escher P, Wahli W. Peroxisome proliferator-activated receptors: Insight into multiple celluar functions. Mut Res, 2000,448(2): 121~38.
  • 6Rieusset J, Andreelli F, Auboeuf D, et al. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor gamma in hunan adipocytes. Diabetes, 1999, 48(4):699~705.
  • 7Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARS): Tissue distribution of PPAR - a, β, and γ in the adult rat. Endocrinology, 1996, 137(1): 354~66.
  • 8Gregoire FM.Adipocyte differentiation: from fibroblast to en doerine cell. Exp Biol Med (Maywood), 2001, 226(11): 997~1002.
  • 9Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem, 2001,276(44) :41245~54.
  • 10Ouali F, Djouadi F, Merlet-Benichou C, et al. Diatary lipids regulate oxidation enzyme gene expression in the developing rat kidney. Am J Physiol, 1998, 275(5 pt 2): F777~84.

同被引文献12

  • 1李贤厚,段滨红,王亦薇,冯琨,杨玉芝.罗格列酮治疗2型糖尿病合并肾病尿微量白蛋白的疗效观察[J].中国误诊学杂志,2004,4(9):1432-1432. 被引量:5
  • 2叶任高,陆再英,主编.内科学[M].第6版.北京:人民卫生出版社,2005,28-30.
  • 3Suzuki D, Toyoda M, Yamamoto N, et al. Relationship between the expression of advanced glyeation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. Intern Med, 2006, 45:435-441.
  • 4Okada T, Wada J, Hida K, et al.Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes, 2006,55: 1666 -1677.
  • 5Marx N, Walcher D, Ivanova N, et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes, 2004,53:2662-2668.
  • 6Tang SC, Leung JC, Chan LY, et al. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferatoractivated receptor-gamma agonist. J Am Sec Nephrol, 2006,17:1633- 1643.
  • 7Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol, 2003,162 : 1123-1137.
  • 8Jensen LJ, Denner L, Schrijvers BF, et al. Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J Endocfinol, 2006,188:493-501.
  • 9Bavirti S, Ghanaat F, Taydk JA. Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patientS with type 2 diabetes independent of diabetic control. Endocrine Practice, 2003,9:487-489.
  • 10Ma LJ, Marcantoni C, Linton MF, et al. Peroxisome proliferator-activated receptor-γ, agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int, 2001,59 : 1899-1910.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部